Testing AZD6234 for Adults With Type 2 Diabetes and Excess Weight
Tests AZD6234 against placebo in adults with type 2 diabetes and excess weight.
Key facts
- Who runs it
- AstraZeneca
- Where
- Busan, Daegu, Daejeon, Incheon, Seoul, and Suwon, South KoreaSee the 6 sitesAlso in 15 other countries, 184 sites
- Trial code
- Registry title
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,500 people, planned
- Started
- 20 Aug 2026
- Expected to end
- 9 Aug 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lenbelintide
- Placebo
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who also have overweight or obesity. It compares AZD6234 with placebo for weight change over 68 weeks.
- Age
- 18 years or older
- Sex
- All sexes and gender identities can join.
- Disease stage
- Type 2 diabetes diagnosed at least 90 days before screening, with BMI of 27 kg/m2 or more and HbA1c between 6.0% (42 mmol/mol) and 10% (86 mmol/mol).
- Earlier treatment
- Diabetes managed with diet and exercise alone, or with a stable dose of an oral glucose-lowering medicine. Stable body weight (5% change or less) for at least 3 months. At least one self-reported unsuccessful attempt to lose weight. No GLP-1 medicine in the 3 months before randomisation. No insulin for type 2 diabetes in the 3 months before screening.
- Biomarker or test result
- HbA1c of 6.0% (42 mmol/mol) to 10% (86 mmol/mol) at screening.
Main reasons for not taking part
- Obesity mainly caused by another hormone disorder
- Type 1 diabetes or diabetes that is not clearly type 2
- Ketoacidosis or hyperosmolar coma/state in the 3 months before screening
- Significant liver or bile duct disease, or ALT or AST of 3.0 X ULN or more, or TBL above 1.5 X ULN
- GLP-1 medicine in the 3 months before randomisation
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Males \& females (inclusive of all gender identities) age ≥18 years
- BMI ≥27 kg/m2
- Diagnosed with T2DM ≥90 days prior to Screening
- HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
- Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
- History of at least one self-reported unsuccessful attempt to lose body weight in lifetime
Who cannot take part
- Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
- Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
- Use of insulin therapy for T2DM within 3 months prior to screening
- Obesity primarily caused by other endocrine disorders
- Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 X ULN; AST ≥ 3.0 X ULN; TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome)
Where in South Korea
Also in 15 other countries, 184 sites
- BusanHospital not named in the registryNot yet recruiting
- DaeguHospital not named in the registryNot yet recruiting
- DaejeonHospital not named in the registryNot yet recruiting
- IncheonHospital not named in the registryNot yet recruiting
- SeoulHospital not named in the registryNot yet recruiting
- SuwonHospital not named in the registryNot yet recruiting
About the trial
What the trial wants to find out
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
The 3 groups in the trial
- AZD6234 Dose 1Treatment being tested
Treatment: Lenbelintide
- AZD6234 Dose 2Treatment being tested
Treatment: Lenbelintide
- PlaceboPlacebo, for comparison
Matching placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
- Plain-language title
- Testing AZD6234 for Adults With Type 2 Diabetes and Excess WeightGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 October 2026